Paradigm Biocapital Advisors LP Merus N.V. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Merus N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,281,954 shares of MRUS stock, worth $273 Million. This represents 10.51% of its overall portfolio holdings.
Number of Shares
4,281,954
Previous 3,369,699
27.07%
Holding current value
$273 Million
Previous $142 Million
58.8%
% of portfolio
10.51%
Previous 7.27%
Shares
8 transactions
Others Institutions Holding MRUS
# of Institutions
217Shares Held
65.3MCall Options Held
311KPut Options Held
556K-
Rtw Investments, LP New York, NY4MShares$255 Million3.23% of portfolio
-
Wellington Management Group LLP Boston, MA3.73MShares$238 Million0.04% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$225 Million17.29% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$216 Million4.09% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.16MShares$201 Million3.03% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.93B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...